AstraZeneca gets US FDA nod for FARXIGA to treat chronic kidney disease
In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…
Recover your password.
A password will be e-mailed to you.